Natural history of human papillomavirus infection in non-vaccinated young males: low clearance probability in high-risk genotypes

详细信息    查看全文

• 作者：T. Cai ; G. Perletti ; F. Meacci ; V. Magri…
• 刊名：European Journal of Clinical Microbiology & Infectious Diseases
• 出版年：2016
• 出版时间：March 2016
• 年：2016
• 卷：35
• 期：3
• 页码：463-469
• 全文大小：438 KB
• 参考文献：1.Forman D, de Martel C, Lacey CJ et al (2012) Global burden of human papillomavirus and related diseases. Vaccine 30(Suppl 5):F12–F23CrossRef PubMed
  2.Kjaer SK, Munk C, Winther JF, Jørgensen HO, Meijer CJ, van den Brule AJ (2005) Acquisition and persistence of human papillomavirus infection in younger men: a prospective follow-up study among Danish soldiers. Cancer Epidemiol Biomarkers Prev 14(6):1528–1533CrossRef PubMed
  3.Repp KK, Nielson CM, Fu R et al (2012) Male human papillomavirus prevalence and association with condom use in Brazil, Mexico, and the United States. J Infect Dis 205(8):1287–1293PubMedCentral CrossRef PubMed
  4.Parisi SG, Cruciani M, Scaggiante R et al (2011) Anal and oral human papillomavirus (HPV) infection in HIV-infected subjects in northern Italy: a longitudinal cohort study among men who have sex with men. BMC Infect Dis 11:150PubMedCentral CrossRef PubMed
  5.Giuliano AR, Nielson CM, Flores R et al (2007) The optimal anatomic sites for sampling heterosexual men for human papillomavirus (HPV) detection: the HPV detection in men study. J Infect Dis 196(8):1146–1152PubMedCentral CrossRef PubMed
  6.Bartoletti R, Cai T, Meliani E et al (2014) Human papillomavirus infection is not related with prostatitis-related symptoms: results from a case–control study. Int Braz J Urol 40(2):247–256CrossRef PubMed
  7.Bartoletti R, Zizzo G, Cai T, Mirone V (2011) Genital condylomata are not the human papilloma virus male infection burden. Eur Urol 60(2):268–269CrossRef PubMed
  8.Giuliano AR, Lee JH, Fulp W et al (2011) Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study. Lancet 377(9769):932–940PubMedCentral CrossRef PubMed
  9.Albero G, Castellsagué X, Lin HY et al (2014) Male circumcision and the incidence and clearance of genital human papillomavirus (HPV) infection in men: the HPV Infection in men (HIM) cohort study. BMC Infect Dis 14:75PubMedCentral CrossRef PubMed
  10.Benevolo M, Mottolese M, Marandino F et al (2008) HPV prevalence among healthy Italian male sexual partners of women with cervical HPV infection. J Med Virol 80(7):1275–1281CrossRef PubMed
  11.Huang Y, Lin M, Luo ZY, Li WY, Zhan XF, Yang LY (2013) Low prevalence of HPV in male sexual partners of HR-HPV infected females and low concordance of viral types in couples in Eastern Guangdong. Asian Pac J Cancer Prev 14(3):1755–1760CrossRef PubMed
  12.Porta M (ed) (2008) A dictionary of epidemiology, 5th edn. Oxford University Press, New York
  13.Mazzoli S, Cai T, Rupealta V et al (2007) Interleukin 8 and anti-chlamydia trachomatis mucosal IgA as urogenital immunologic markers in patients with C. trachomatis prostatic infection. Eur Urol 51(5):1385–1393CrossRef PubMed
  14.Muñoz N, Bosch FX, de Sanjosé S et al (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348(6):518–527CrossRef PubMed
  15.Giuliano AR, van der Loeff MF, Nyitray AG (2011) Circumcised HIV-infected men and HPV transmission. Lancet Infect Dis 11(8):581–582CrossRef PubMed
  16.Kyo S, Inoue M, Koyama M, Fujita M, Tanizawa O, Hakura A (1994) Detection of high-risk human papillomavirus in the cervix and semen of sex partners. J Infect Dis 170(3):682–685CrossRef PubMed
  17.Markowitz LE, Sternberg M, Dunne EF, McQuillan G, Unger ER (2009) Seroprevalence of human papillomavirus types 6, 11, 16, and 18 in the United States: National Health and Nutrition Examination Survey 2003–2004. J Infect Dis 200:1059–1067CrossRef PubMed
  18.Parada R, Morales R, Giuliano AR, Cruz A, Castellsagué X, Lazcano-Ponce E (2010) Prevalence, concordance and determinants of human papillomavirus infection among heterosexual partners in a rural region in central Mexico. BMC Infect Dis 10:223PubMedCentral CrossRef PubMed
  19.Campion MJ, Singer A, Clarkson PK, McCance DJ (1985) Increased risk of cervical neoplasia in consorts of men with penile condylomata acuminata. Lancet 1:943–946CrossRef PubMed
  20.Liu M, He Z, Zhang C et al (2014) Prevalence, incidence, clearance, and associated factors of genital human papillomavirus infection among men: a population-based cohort study in rural China. Cancer Epidemiol Biomarkers Prev 23(12):2857–2865CrossRef PubMed
  21.Giuliano AR, Lu B, Nielson CM et al (2008) Age-specific prevalence, incidence, and duration of human papillomavirus infections in a cohort of 290 US men. J Infect Dis 198:827–835CrossRef PubMed
  22.Lu B, Wu Y, Nielson CM et al (2009) Factors associated with acquisition and clearance of human papillomavirus infection in a cohort of US men: a prospective study. J Infect Dis 199:362–371CrossRef PubMed
  23.Gupta A, Arora R, Gupta S et al (2006) Human papillomavirus DNA in urine samples of women with or without cervical cancer and their male partners compared with simultaneously collected cervical/penile smear or biopsy specimens. J Clin Virol 37(3):190–194CrossRef PubMed
  24.Pathak N, Dodds J, Zamora J, Khan K (2014) Accuracy of urinary human papillomavirus testing for presence of cervical HPV: systematic review and meta-analysis. BMJ 349:g5264PubMedCentral CrossRef PubMed
  25.Tanzi E, Bianchi S, Fasolo MM et al (2013) High performance of a new PCR-based urine assay for HPV-DNA detection and genotyping. J Med Virol 85(1):91–98CrossRef PubMed
  
• 作者单位：T. Cai (1)
  G. Perletti (2) (3)
  F. Meacci (4)
  V. Magri (5)
  P. Verze (6)
  A. Palmieri (6)
  S. Mazzoli (4)
  R. Santi (7)
  G. Nesi (7)
  V. Mirone (6)
  R. Bartoletti (8)
  
  1. Department of Urology, Santa Chiara Regional Hospital, Largo Medaglie d’Oro, 9, 38123, Trento, Italy
  2. Biomedical Research Division, Department of Theoretical and Applied Sciences, University of Insubria, Varese, Italy
  3. Department of Basic Medical Sciences, University of Ghent, Ghent, Belgium
  4. Sexually Transmitted Diseases Centre, Santa Maria Annunziata Hospital, Florence, Italy
  5. Urology Clinic, Istituti Clinici di Perfezionamento, Milan, Italy
  6. Department of Urology, University Federico II of Naples, Naples, Italy
  7. Division of Pathological Anatomy, Department of Critical Care Medicine and Surgery, University of Florence, Florence, Italy
  8. Department of Urology, University of Florence, Florence, Italy
  
• 刊物类别：Biomedical and Life Sciences
• 刊物主题：Biomedicine
  Medical Microbiology
  Internal Medicine
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1435-4373

文摘

In this study, we aimed to investigate the clearance of type-specific genital human papillomavirus (HPV) infection in heterosexual, non-HPV-vaccinated males whose female partners were positive to HPV DNA tests. All consecutive men attending the same sexually transmitted diseases (STD) centre between January 2005 and December 2006 were considered for this study. All subjects (n = 1009) underwent a urologic visit and microbiological tests on first void, midstream urine and total ejaculate samples. One hundred and five patients were positive for HPV DNA (10.4 %; mean age: 34.8 ± 5.8 years) and consented to clinical examination and molecular diagnostic assays for HPV detection scheduled every 6 months (median surveillance period of 53.2 months). HPV genotypes were classified as high risk, probable high risk and low risk. HPV-positive samples which did not hybridise with any of the type-specific probes were referred to as positive non-genotypeable. At enrollment, the distribution of HPV genotypes was as follows: high-risk HPV (n = 37), probable high-risk HPV (n = 6), low-risk HPV (n = 23) and non-genotypeable HPV (n = 39). A high HPV genotype concordance between stable sexual partners emerged (kappa = 0.92; p < 0.001). At the end of the study, 71/105 (67.6 %) subjects were negative for HPV (mean virus clearance time: 24.3 months). With regard to the HPV genotype, virus clearance was observed in 14/37 (37.8 %) high-risk HPV cases, 6/6 (100 %) probable high-risk HPV cases, 20/23 (86.9 %) low-risk HPV cases and 31/39 (79.5 %) non-genotypeable cases. The high-risk HPV genotypes showed the lowest rate and probability of viral clearance (p < 0.001). In our series, high-risk HPV infections were more likely to persist over time when compared with other HPV genotypes.